

Memo

To: DFCI Industry Partners
From: Jiale Dai, Ph.D., RPh, Research Pharmacy (Email: jiale_dai@dfci.harvard.edu; Tel: 857-215-5009)
Date: March 16, 2020
Re: Direct mailing of investigational drugs to patients on clinical trials

In response to the COVID-19 pandemic, Research Pharmacy at Dana-Farber Cancer Institute is working closely with study teams and sponsors to deliver investigational drug treatments to active patients without interruption.

Both the United States and the State of Massachusetts have declared a state of emergency. Given the rising number of confirmed cases in the Boston area, many of our patients are increasingly concerned about coming in person to our hospital to pick up their investigational medications. Out of concern for the safety of our patients, Research Pharmacy is requesting authorization to mail investigational medications directly to patients' residences when deemed appropriate and necessary. Our goal is to adhere to the protocol stipulations as closely as possible and provide continuous investigational drug treatments without delays. We sincerely hope you agree with our plan and provide us blanket sponsor approval for us to mail these investigational drugs to Dana-Farber patients.

Our plan is to continue to monitor the COVID-19 situation closely and revert back to our usual SOPs when the pandemic is over. We feel the temporary measures we are proactively taking is in the best interest of our patients with respect to safety and integrity of ongoing clinical trials at Dana-Farber under these emergency circumstances.

Please let us know if you agree with our plan. Due to the time sensitivity of this matter, **please email Jiale Dai at jiale_dai@dfci.harvard.edu as soon as possible.** We sincerely appreciate your assistance in ensuring the safety of our patients.